Viatris (NASDAQ:VTRS) is a global healthcare company formed in November 2020 through the merger of Mylan and Upjohn, a division of Pfizer. Headquartered in Canonsburg, Pennsylvania, the company offers a broad portfolio of generic, branded and biosimilar medicines. Its establishment combined decades of pharmaceutical expertise with a strategic focus on expanding patient access to high-quality, affordable therapies across a diverse range of therapeutic areas.
The company’s product range spans key health categories including cardiovascular and metabolic diseases, infectious diseases, respiratory conditions, oncology, women’s health and immunology. Viatris manufactures and distributes an extensive array of oral solid dose, injectables and biologics, as well as over-the-counter solutions. Through partnerships and licensing agreements, it also provides biosimilar and novel therapies designed to address unmet medical needs and help reduce healthcare costs.
Viatris operates in more than 165 countries and territories, serving patients, healthcare professionals and health systems worldwide. Its global supply chain and manufacturing footprint enable it to reach both developed and emerging markets, with a particular emphasis on ensuring the reliable delivery of essential medicines. The company’s commitment to sustainability and responsible business practices underpins its efforts to strengthen healthcare infrastructure and improve patient outcomes in underserved regions.
Led by President and Chief Executive Officer Michael Goettler, Viatris draws on a leadership team with deep industry experience to drive strategic growth, operational excellence and innovation. Through ongoing investments in research, development and strategic collaborations, the company aims to advance its pipeline, enhance therapeutic access and support long-term value creation for patients and stakeholders around the world.
